On Tuesday, December 11, Finnegan client Eli Lilly and Company filed suit in the U.S. District of Eastern Virginia claiming the U.S. Patent and Trademark Office “acted arbitrarily in failing to extend its patent for a cancer treatment solution and methods by an additional year and a half.” The lawsuit concerns the USPTO’s patent term adjustment calculation on Eli Lilly’s U.S. Patent Number 8,114,901. Eli Lilly and Company is represented by Finnegan in this matter.
Media Mention
Women in Business Law Americas Awards 2024: Three Finnegan Attorneys Shortlisted
April 7, 2024
Press Release
Finnegan and BMW Group Successfully Demolish Non-Practicing Entity NorthStar’s Efforts
April 3, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.